Novian Health

  • About Us
    • Overview
    • Management
    • Board Of Directors
    • Investors
  • Research & Products
    • Novilase® Breast Therapy
    • Clinical Trials & Registries
    • Publications
    • Intellectual Property
  • News
    • News & Press Releases
    • Media Coverage
    • Upcoming Events
  • Contact
    • Careers

Novian Health Founder Is Honored as Breast Cancer Leader by Chicago Komen Affiliate (20 Oct 2011)

October 20, 2011 by Novian Health

Oct. 20, 2011
Contact: Liz Dowling, (415) 3888-2794
Dowling & Dennis Public Relations
E-mail:Liz@DowlingDennis.net

Dr. Kambiz Dowlat, Developer of Novilase Laser Therapy for Breast Tumors, Is One of the Inaugural ‘Pink Tie Guys’ CHICAGO – Kambiz Dowlat M.D., founder of Novian Health, has been honored by the Chicagoland Area Affiliate of Susan G. Komen for the Cure® in the inaugural class of Pink Tie Guys.

Dr. Dowlat, developer of Novilase® image-guided laser therapy for breast tumors, is one of what the organization called “an exclusive group of KoMEN making a difference in the fight against breast cancer.”

The Pink Tie Guys, who were nominated by the community and selected by the Komen Chicagoland Board of Directors, were honored Oct.13 at Tribune Media Group’s Pink Tie Gala attended by Illinois Gov. Pat Quinn. In addition to Dr.Dowlat, former Chicago Mayor Richard M. Daley was among the honorees.

“This prestigious award demonstrates yet again the value of Dr. Dowlat’s research. It’s a gratifying recognition of his longstanding dedication to improving women’s breast health,” said Henry “Chip” Appelbaum,President and CEO of NovianHealth.

Dr. Dowlat, a Professor of Surgery atRush University Medical Center, is a pioneer of minimally invasive breast cancer procedures. He performed the groundbreaking research that formed the basis for the multi-center breast cancer trial that Novian is launching, having recently received approval of an investigational device exemption(IDE) from the FDA.

Novian developed the Novilase ILT System for the ablation of small (up to 20mm) malignant breast tumors. The company has previously received FDA 510(k)clearance for the treatment of breast fibroadenomas and currently offers Novilase at breast centers around the country that are participating in its ABLATE registry.

The Chicagoland Affiliate of Susan G. Komen for the Cure® was established in 1997 and held the first Susan G. Komen Chicago Race for the Cure®. The affiliate has awarded nearly $11 million towards the fight against breast cancer by funding grassroots breast health education and breast cancer screening and treatment projects, as well as national research.

About Novilase

Novilase is a laser-based device for destroying tumors. This minimally invasive alternative to conventional surgery provides a safe tumor treatment alternative while preserving the patient’s options for additional procedures or adjunctive therapies. This image-guided outpatient procedure does not require general anesthetic or a hospital stay. Multiple tumors can be treated during a single visit. Therapy outcomes may be assessed using a variety of currently available imaging technologies and other methods. Therapy consists of physician placement of two small gauge needles into the tumor site after localanesthetic, followed by initiation of the computer-controlled Novilase system. Treatment times vary from 15-30 minutes

About Novian Health

Novian Health Inc., located in Chicago, is a privately held medical device company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy (ILT). Developed as an alternative to surgery, the company’s technology uses parametrically controlled heating for the ablation of tumors.Image-guided treatment of breast tumors is the first application of the technology, and Novilase also has the potential to treat tumors elsewhere in the body.
For more information, call (312) 266-7200 or access www.novianhealth.com and www.novilase.com

Download PDF

Related Posts

  • Novian Health Receives FDA Approval to Study Breast Cancer Therapy (14 July 2011)
  • Novian Health Closes $11 Million in Funding for Breast Cancer Clinical Trials (04 Feb 2013)
  • Novian Health Begins Breast Cancer Clinical Trial (12 April 2012)
  • Novian Health Awarded New Patent for Breast Tumor Treatment Technology (28 Sept 2011)
  • Novian Health Awarded New Patent for Breast Cancer Treatment Technology (05 Dec 2013)

Filed Under: Press Release 2011

Recent Posts

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

ARCHIVES

  • December 2022
  • September 2021
  • August 2021
  • July 2021
  • February 2021
  • September 2020
  • June 2020
  • September 2019
  • July 2019
  • June 2019
  • December 2015
  • December 2014
  • September 2014
  • May 2014
  • December 2013
  • April 2013
  • February 2013
  • April 2012
  • October 2011
  • September 2011
  • July 2011
  • November 2010
  • December 2009
  • November 2009
  • October 2009
  • May 2009
  • June 2008
  • March 2008
  • October 2007
  • June 2007

Categories

  • Archives
  • Press Release 2011
  • Press Release 2012
  • Press Release 2013
  • Press Release 2014
  • Press Release 2015
  • Press Release 2019
  • Press Release 2020
  • Press Release 2021
  • Press Release 2022

CONTACT US

Novian Health Inc.
(Headquarters)
Novian Health Inc.
(Manufacturing)
222 W Merchandise Mart Plaza
Suite 1230
Chicago, Illinois 60654
1205 E State Avenue
Tonganoxie, KS 66086
Office: 312-266-7200 Office: 312-266-7200
Fax: 312-266-7202 Fax: 312-266-7202
Email: info@novianhealth.com Email: info@novianhealth.com

    

LATEST NEWS

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

Copyright © 2023 Novian Health. All Rights Reserved. Powered by